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Abstract 
Background: Mass drug administration (MDA) appears to be effective in reducing the risk of malaria parasitaemia. 
This study reports on programmatic coverage and compliance of MDA using artemisinin‑based combination therapy 
(ACT) in four shehias (smallest administration unit) that had been identified as hotspots through Zanzibar’s malaria 
case notification surveillance system.
Methods: Mass drug administration was done in four shehias selected on the basis of: being an established malaria 
hot spot; having had mass screening and treatment (MSaT) 2–6 weeks previously; and exceeding the epidemic alert 
threshold of 5 cases within a week even after MSaT. Communities were sensitized and MDA was conducted using a 
house‑to‑house approach. All household members, except pregnant women and children aged less than 2 months, 
were provided with ACT medicine. Two weeks after the MDA campaign, a survey was undertaken to investigate com‑
pletion of ACT doses.
Results: A total of 8816 [97.1% of eligible; 95% confidence interval (CI) 96.8–97.5] people received ACT. During post 
MDA surveys, 2009 people were interviewed: 90.2% reported having completed MDA doses; 1.9% started treatment 
but did not complete dosage; 4.7% did not take treatment; 2.0% were absent during MDA and 1.2% were ineligible 
(i.e. infants <2 months and pregnant women). Main reasons for failure to complete treatment were experience of 
side‑effects and forgetting to take subsequent doses. Failure to take treatment was mainly due to fear of side‑effects, 
reluctance due to lack of malaria symptoms and caregivers forgetting to give medication to children.
Conclusion: Mass drug administration for malaria was well accepted by communities at high risk of malaria in Zan‑
zibar, with high participation and completion rates. Further work to investigate the potential of MDA in accelerating 
Zanzibar’s efforts towards malaria elimination should be pursued.
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Background
Malaria was the leading cause of morbidity and mortal-
ity in Zanzibar prior to 2003, with malaria endemicity 
being classified as moderate to high (i.e. parasitaemia 
among symptomatic patients tested was 35–40%) [1]. In 
response to the malaria burden, the Zanzibar Malaria 
Control Programme—in collaboration with bilateral, 
multilateral and non-governmental partners—scaled up 
prevention and control efforts, including: artemisinin-
based combination therapy (ACT); insecticide-treated 
nets (ITNs); indoor residual spraying of households 
with insecticide (IRS); and intermittent preventive 
treatment for pregnant women (IPTp) with sulfadox-
ine–pyrimethamine (SP) [2–4]. Over the past decade 
these efforts changed malaria endemicity in Zanzibar 
from hyper- to hypo-endemic, with parasite prevalence 
dropping to and being maintained at <1% for the previ-
ous 3 years [1, 4].
Building on the success of these efforts and in align-
ment with global guidance [5], Zanzibar is now target-
ing malaria elimination on both Unguja and Pemba 
islands: the goal is to achieve zero locally acquired 
cases by 2018 by achieving and maintaining 100% cov-
erage with appropriate prevention measures [6]. While 
malaria elimination relies upon a similar mix of inter-
ventions as during the malaria control phase (i.e. case 
management, vector control, and surveillance), it 
requires more intensified, rapid, and targeted responses, 
especially for targeting transmission hotspots and spe-
cific high-risk populations [7–9]. The Zanzibar Malaria 
Elimination Programme (ZAMEP) is able to identify 
hotspots through its malaria case notification (MCN) 
(“Coconut”) surveillance system, which tracks daily 
facility-based malaria cases for real-time decision-mak-
ing and active case detection through household screen-
ing and treatment (HSaT).
One potential strategy for targeted interventions in a 
malaria elimination setting is focal mass drug adminis-
tration (MDA) in high-risk populations. Although falling 
out of favour due to efficacy concerns during the eradica-
tion era in the 1960s, MDA has re-emerged as a poten-
tial strategy for malaria elimination and eradication [10, 
11]. Use of MDA since the eradication era has mainly 
been preventative therapy and seasonal chemopreven-
tion; however, an argument for MDA is that diagnosis 
can be hampered by lack of biomarkers of the liver stage 
of malaria and limitations of currently available detection 
methods for lower density blood stage infections [12, 13]. 
A recent systematic literature review found that: (1) MDA 
has been used in large-scale malaria control, elimination 
and outbreak response efforts, with community partici-
pation and at least 80% coverage of the target population 
being important factors for a successful MDA campaign; 
(2) MDA and mass chemoprophylaxis probably contrib-
uted to reducing parasite prevalence in certain interven-
tion settings; and (3) select MDA programmes have been 
considered successful based on qualitative assessments 
other than efficacy [14]. Renewed interest in MDA as an 
approach for interrupting transmission is based on the 
availability of effective anti-malarial drugs with transmis-
sion reducing characteristics as well as mathematic mod-
eling studies showing the epidemiological impact of the 
intervention in settings with low transmission intensity 
and during periods of low vector densities [15]. However, 
there is evidence to suggest that effectiveness of MDA is 
often not sustained beyond 6 months [16].
Taking into account the current pre-elimination set-
ting of Zanzibar, MDA might have a significant effect 
when used focally in areas at risk of high-transmission, 
especially before the peak malaria transmission season. 
This study reports on programmatic coverage and com-
pliance of MDA using ACT in four shehias (the smallest 
administrative unit in Zanzibar comprising of 2000–5000 
population) that had been identified as hotspots through 
Zanzibar’s MCN surveillance system.
Methods
Study settings
There are 331 shehias in Zanzibar, of which four were 
purposively selected for the MDA intervention, because 
they: (1) were established malaria transmission hotspots 
with annual malaria incidence >20/1000 population; 
(2) had received mass screening and treatment (MSaT) 
2–6  weeks earlier; and (3) had exceeded the epidemic 
alert threshold of 5 cases or more reported within a week 
even after MSaT intervention, with MDA considered as 
an additional intervention [17]. Figure 1 shows the loca-
tion of the shehias where the MDA was undertaken in 
June 2013: Finya and Chimba are located in Micheweni 
District of Pemba, while Uzi and Ng’ambwa is a penin-
sula in the South District of Unguja.
MDA implementation
Drug used for MDA
Table 1 shows the ACT preparations and dosages used 
during the MDA. The main ACT used was dihydroar-
temisinin/piperaquine phosphate (Duo-Cotecxin®, 
Beijing Holley-Cotec Pharmaceutical Co Ltd, China). 
In Uzi and Ng’ambwa, artemisinin and piperaquine 
 (Artequick®, Artepharm, China) was also dispensed 
due to shortages of Duo-Cotecxin. Duo-cotecxin and 
 Artequick® were considered appropriate for the MDA 
pilot, because both are not used in the routine treat-
ment of malaria in Zanzibar. However, based on the 
manufacturers recommendations, Duo-Cotecxin® 
40/320  mg tablets is not suitable for children aged 
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<6 months while  Artequick® 62.5/375 mg tablets is not 
suitable for children age <7  years [18, 19]; therefore, 
artesunate–amodiaquine (ASAQ)  Winthrop® was dis-
pensed instead.
Population eligible for MDA
All people living in the MDA pilot areas were eligible for 
treatment, except infants <2 months of age, and pregnant 
women in the first trimester of pregnancy.
Training
In each shehia, ten teams comprising of a healthcare 
worker (i.e. drug dispenser), an administration leader 
(i.e. local guide) and a recorder (to complete MDA mon-
itoring forms) were trained to conduct MDA. In addi-
tion to the drug distribution team, a team comprising a 
health promotion specialist and a local guide were allo-
cated to each shehia to conduct community mobilization 
and top-up ITN distribution on the day of the MDA. A 
Fig. 1 Map of Zanzibar showing the MDA shehias
Table 1 List of ACT preparations and dosages used during the MDA
a Used in Uzi and Ng’ambwa only
b Dispensed for children not eligible for Duo-Cotecxin® 40/320 mg tablets (age <6 months) and  Artequick® 62.5/375 mg tablets (age <7 years) [18, 19]
ACT drug Formulation Age group Daily dosage (tablets) Number of days
Dihydroartemisinin and Piperaquine Phosphate (Duo‑Cotecxin®) 40/320 mg tablets 6 months–1 year ½ 3
2–7 years 1 3
8–13 years 2 3
≥14 years 3 3
Artemisinin and Piperaquine  (Artequick®)a 62.5/375 mg tablets 7–10 years 1 2
11–15 years 1½ 2
≥16 years 2 2
Artesunate Amodiaquine  Winthrop®b 25/67.5 mg tablets 2–11 months 1 3
50/135 mg tablets 1–5 years 1 3
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days’ training was conducted to drug distribution teams 
with the objective of explaining the rationale and impor-
tance of MDA, filling MDA forms and dispensing of 
ACT.
Community mobilization
Two days prior to MDA implementation, a series of com-
munity mobilization events were undertaken in each 
shehia, including radio programmes on malaria preven-
tion and response activities, house-to-house communi-
cation through local leaders, and public announcements 
through town criers. The information focused on what, 
why, when and how MDA would be carried out. Informa-
tion leaflets on the MDA activity and malaria prevention 
in Swahili language were also distributed in the target 
shehias. After the MDA, public announcements contin-
ued on the second and the third day with messages tar-
geted at reminding communities to take the second and 
the thirds ACT doses. Information on malaria prevention 
through consistent use of bed nets was also delivered.
Drug distribution
The MDA was undertaken from house-to-house. In each 
household, all members were enumerated. Women of 
child-bearing age were asked if they were in the first tri-
mester of pregnancy to determine eligibility for treat-
ment. All eligible persons present were offered ACT, with 
the first dose being taken as a directly observed treatment 
(DOT). Dosage for subsequent days (day 2 and 3) was 
dispensed in packets labeled with the name for each eli-
gible recipient. For those that were not present during the 
household visit, drugs were dispensed in a labeled packet 
and left with the head of the household. Instructions on 
when the subsequent doses would be taken were provided 
to all MDA adult participants. Parents and guardians were 
provided with information on dosing of children. After 
the MDA, public announcements were done in the com-
munity on days 2 and 3 post-MDA reminding participants 
to take the dose for the respective day.
Post MDA survey
Two weeks after the MDA, a survey was done to estimate 
completion of ACT doses distributed; investigate reasons 
for not completing MDA doses; investigate side-effects 
following MDA; and explore willingness of participants 
to take part in MDAs in the future.
Using an internet-based sample size calculator (http://
www.raosoft.com/samplesize.html), sample size was calcu-
lated to estimate 50% completion of all three MDA doses 
within a 5% error margin, given a 5% level of significance 
and 95% confidence level. Calculations were adjusted for 
a design effect of 2.0 to allow for household clustering of 
observations, as well as a 10% non-response rate, yielding a 
minimum sample size of 750 individuals required per she-
hia. Assuming—based on operational programme imple-
mentation experience—a household size of 5, at least 150 
households were required to be surveyed in each shehia. A 
list of all households that would be eligible to participate in 
the MDA was obtained for each shehia. To ensure the sam-
ple’s uniform distribution across the shehia, household lists 
were ordered by sub-shehia prior to 150 households being 
selected using systematic random sampling.
Data collection and analysis
Customized forms were designed to collect data dur-
ing the MDA distribution and post-MDA survey. MDA 
monitoring forms included a household census, eligi-
bility for participation in MDA and ACT dosage. Post 
MDA forms included a household census, questions on 
MDA participation, reasons for MDA non-completion, 
side-effects and willingness to participate in MDA in 
the future. Data were completed by health care work-
ers who were experienced in undertaking household 
surveys and who had received a day’s training on the 
survey protocol. Data from the MDA monitoring form 
and post-MDA survey were entered using Microsoft 
 Excel® (Microsoft Corporation, Redmond, WA) spread-
sheets. Statistical analysis was conducted using Stata 
12.0 (Stata Corporation, College Station, TX). Data for 
Uzi and Ng’ambwa were combined together for analy-
sis, because the two shehia comprise a peninsula on 
Unguja. Descriptive statistics were used to summarize 
the age and gender distribution of the MDA populations 
and post-MDA sample, MDA treatment coverage and 
MDA completion. Differences in proportions were com-
pared using the χ2 test.
Results
Age and gender characteristics of study population
A total of 9076 participants in 2001 households were 
enumerated in the four districts targeted for MDA; a 
total of 2009 participants were enumerated in 413 house-
holds during the post MDA survey. Compared to Chimba 
and Finya, the mean age of the population of Uzi and 
Ng’ambwa was slightly higher; however, there was no sta-
tistically significant difference in the gender distribution 
across shehias (Table 2).
MDA treatment coverage
Overall, a total of 8816 out 9076 [97.1%; 95% confi-
dence interval (CI) 96.8–97.5] people enumerated 
received treatment, with MDA coverage between dis-
tricts not significantly different, ranging from 95.7%; 
(95% CI 94.0–96.4) in Uzi and Ng’ambwa to 98.0% (95% 
CI 97.4–98.4) in Chimba. Of the 260 people that did not 
receive treatment, the majority (65.8%) were absent from 
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the household at the time of the MDA; the remainder 
were not eligible to receive treatment [i.e. infants under 
2 months of age (14.6%) and pregnant women in the first 
trimester (19.6%)] (Table 3; Fig. 2).
MDA treatment completion
A sample of 2009 people were interviewed during post-
MDA survey, of whom: 90.2% reported having completed 
MDA doses; 1.9% started treatment but did not complete 
Table 2 Age and gender characteristics of population participating in MDA and sample of post MDA participants
SD standard deviation
Population Number of households Number of people enumerated Mean age (SD) years Male Gender (%)
Population participated in MDA
 Chimba 672 3399 20.6 (17.2) 50.3
 Finya 471 2495 20.8 (17.5) 49.5
 Uzi & Ng’ambwa 858 3182 22.8 (17.8) 51.5
Total 2001 9076 21.4 (17.5) 50.5
Sample participated in post MDA survey
 Chimba 150 746 19.9 (17.2) 49.3
 Finya 150 770 20.7 (17.0) 50.6
 Uzi & Ng’ambwa 113 493 22.4 (17.5) 51.9
Total 413 2009 20.9 (17.3) 50.5
Table 3 MDA treatment coverage by shehia
CI confidence interval
Shehia People enumerated People treated Proportion treated % (95% CI)
Chimba 3399 3331 98.0 (97.5–98.4)
Finya 2495 2439 97.8 (97.1–98.3)
Uzi & Ng’ambwa 3182 3046 95.7 (94.9–96.4)
Total 9076 8816 97.1 (96.8–97.5)
9,076 
people enumerated in 
four districts pre-MDA
Reason for not receiving treatment 
171 absent at me of MDA
51 pregnant women in first trimester
38 infants under 2 months of age
1,944 
people received 
MDA ACTs
8,816
people received 
MDA ACTs
2,009 
people surveyed post 
MDA
Reason for not receiving treatment 
40 absent at me of MDA
25 pregnant women in first trimester or 
infants under  2 months of age
1,812 
completed daily MDA 
ACT dose over three 
days
Reason for not compleng full MDA course
94 did not take ACTs
38 did not complete course of ACTs
MDA Post – MDA Survey
Fig. 2 Consort chart of study
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dosage; 4.7% received medicine but did not take treat-
ment; 2.0% did not receive medicine, because they were 
absent during MDA; and 1.2% were not eligible to receive 
treatment (infants and first trimester pregnant women) 
(Table 4; Fig. 2). Of the 38 people not completing treat-
ment, two fifths did not provide any reason; the remain-
der provided a range of reasons for non-compliance, 
including experienced side-effects, fear of side-effects, 
and forgetting to take treatment. Reasons for failure to 
take treatment were: fear of side-effects; did not have 
fever; forgot to take treatment or forgot give treatment to 
children; fasting; busy with daily chores; and insufficient 
information about MDA. A total of 94 (i.e. 5.2% of those 
taking treatment) reported side-effects including: mus-
cular aches (22.3%); dizziness (21.3%); abdominal pain 
(16.0%); vomiting (11.7%); headache (9.6%); fever (5.3%); 
sneezing (4.3%); diarrhoea (3.2%); nausea (3.2%); other 
(3.2%). The majority (94.2%) of 2009 survey participants 
reported that they would take part in MDA in the future.
Discussion
This study presents findings on the community’s accept-
ability, completion and perceptions after focal MDA with 
ACT intended to mitigate increased seasonal malaria 
transmission in Zanzibar. MDA was conducted within 
communities as a response to an increase in malaria 
cases in the four shehias defined as hotspots where MDA 
was recommended because—although MSaT had been 
done a few weeks prior—the number of malaria cases 
in these shehias continued to increase. The rationale 
for MDA was to provide appropriate treatment to clear 
malaria parasites in the population so as to prevent on-
going transmission in malaria hotspots with intense 
transmission. The findings of the pilot presented here 
showed high MDA participation (97.1%) and accept-
ance by the communities targeted, with high completion 
of ACT doses (90.2%) among participants who received 
the medication. This finding was most likely attributed to 
the intensive community sensitization and mobilization 
activities that took place prior to the MDA, including 
the house-to-house approach as well as the post-MDA 
public announcements to remind people to complete 
subsequent doses. The findings also suggest that commu-
nity sensitization was effective, as the majority (94.2%) of 
survey participants reporting that they would take part in 
future MDAs. This suggests that MDA can be considered 
as a practical intervention in persisting malaria hotspots, 
particularly if active case detection efforts such as MSaT 
and HSaT fail to adequately curb transmission.
The post-MDA survey findings showed that the rea-
sons for failure to complete the ACT doses were fear of 
side-effects such as abdominal pain, headaches, vomit-
ing, dizziness, sneezing, muscular aches, fever, nausea 
and body malaise. Similar findings were observed in 
studies conducted in The Gambia where barriers of the 
MDA campaign included the perception and fear of the 
community members on the side-effects of the drugs and 
procedures [20, 21]. These misconceptions by the partici-
pants and misunderstandings about the medication can 
contribute greatly to the lack of adherence to an MDA 
[22]. Similarly, fear of side-effects from the drugs leading 
to decreased MDA coverage has also been reported in 
MDA for other parasitic diseases, e.g. lymphatic filaria-
sis [23–27]. Other reasons for non-compliance reported 
by participants in Zanzibar included: forgetting to take 
treatment; insufficient information about MDA; reluc-
tance to take drugs without malaria symptoms; fasting; 
and busy with daily chores. The number of pills required 
for a full ACT regimen has also been shown to discour-
age adherence to the MDA programme [28]. Single dose 
treatment, possibly under DOT, could enhance compli-
ance for malaria MDA.
As neglected tropical disease MDAs have shown in 
multiple countries [29–31], in order to maximize MDA 
participation, misconception and fears of side-effects 
within the target population need to be addressed at 
the start of the activity and frequent communication 
should be maintained throughout the MDA period 
through community education and training of health 
care workers [14, 26, 32]. This is particularly salient if 
several rounds of MDA were to be conducted in order 
to have a more lasting impact on malaria transmission. 
Table 4 MDA completion of ACT doses in Chimba, Finya, Uzi and Ng’ambwa shehias
Shehia Survey participants Participation in MDA (%)
Completed MDA 
dose
Started treatment 
but MDA dose not 
completed
Refused to take 
MDA
Not present dur-
ing MDA
Not eligible 
for MDA
Chimba 746 89.4 2.9 5.4 1.2 1.1
Finya 770 91.3 1.0 4.5 1.8 1.3
Uzi and Ng’ambwa 493 89.7 1.6 3.9 3.7 1.2
Total 2009 90.2 1.9 4.7 2.0 1.2
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In addition, community sensitization should involve vil-
lage leaders to enhance participation from community 
members [20]. The importance of educating the target 
community with correct information regarding the drug, 
procedures to be taken and the possible side-effects 
helps to enhance adherence. The results of this study 
show that MDA is a practical response intervention in 
low transmission settings; however, further research is 
needed to investigate the effectiveness of MDA in the 
four shehias.
This is the first study to pilot MDA as an intervention 
for malaria elimination in Zanzibar. The study has several 
potential limitations. Firstly, the pilot was done in a few 
shehias selected purposively and, therefore, may not be 
generalizable to the whole of Zanzibar. Secondly, compli-
ance for treatment was measured based on self-reports 
by the participants, which may be subject to recall bias or 
over-reporting. Finally, the study was designed as a fea-
sibility study embedded in a larger operational program, 
and not as an efficacy study to measure the impact of 
MDA on malaria morbidity and/or transmission. If MDA 
does become part of the intervention package to ensure 
malaria transmission remains low, particularly in hot-
spots, then a robust monitoring and evaluation frame-
work and protocol to measure the intervention’s efficacy 
will have to be designed.
Conclusion
This study demonstrates that MDA for malaria was fea-
sible and highly accepted by communities at high risk of 
malaria in Zanzibar, with high participation and comple-
tion rates, even though they had recently been targeted 
for MSaT. Together with other preventative measures, 
MDA has the potential to contribute to interrupting 
transmission of malaria and accelerate ZAMEP’s efforts 
towards malaria elimination.
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